Mirati Therapeutics, Inc. Stock: price and insider trades · United States · SEC (Form 4)

About Mirati Therapeutics, Inc.

Mirati Therapeutics, Inc. (NASDAQ: MRTX) is a U.S.-based biopharmaceutical company focused on precision oncology. For French-speaking investors, it fits squarely within the Health & Pharma sector, with a research-driven profile centered on targeted cancer therapies and biomarker-led drug development. The company was founded in 1995 and was historically headquartered in San Diego, California, United States. Over time, Mirati built its identity around discovering and developing therapies for genetically defined cancers, especially tumors driven by KRAS alterations. Its corporate trajectory changed materially when Bristol Myers Squibb announced and subsequently completed the acquisition of Mirati in 2024, effectively ending Mirati’s life as an independent listed issuer.([news.bms.com](https://news.bms.com/news/corporate-financial/2024/Bristol-Myers-Squibb-Completes-Acquisition-of-Mirati-Therapeutics-Strengthening-and-Diversifying-Oncology-Portfolio/default.aspx?utm_source=openai)) Mirati’s lead asset is KRAZATI (adagrasib), a targeted KRAS G12C inhibitor. The drug was initially developed for previously treated KRAS G12C-mutated non-small cell lung cancer, and its development program later expanded into other solid tumors, including KRAS G12C-mutated colorectal cancer. Recent Bristol Myers Squibb disclosures, which now cover Mirati’s asset base, highlighted important milestones for KRAZATI, including positive KRYSTAL-12 phase 3 data and FDA accelerated approval in 2024 for KRAS G12C-mutated colorectal cancer. These events reinforced the clinical relevance of Mirati’s core platform and validated the company’s precision-oncology strategy.([investors.bms.com](https://investors.bms.com/iframes/press-releases/press-release-details/2024/Bristol-Myers-Squibb-Announces-U.S.-FDA-Accelerated-Approval-of-KRAZATI-adagrasib-in-Combination-with-Cetuximab-for-Adult-Patients-with-Previously-Treated-KRAS-G12C-Mutated-Locally-Advanced-or-Metastatic-Colorectal-Cancer-CRC/default.aspx?utm_source=openai)) From a competitive standpoint, Mirati differentiated itself through a highly focused oncology franchise built on molecular targeting and the treatment of underserved patient subsets. In biopharma, this model can create attractive value if the company can demonstrate strong clinical efficacy, manageable safety, and a clear regulatory path. Before the acquisition, Mirati competed with other targeted oncology developers, but its profile rose substantially as KRAZATI advanced through late-stage development and into the market. The broader pipeline also included early clinical programs in KRAS-related oncology and other tumor targets, which made Mirati an interesting innovation asset even beyond the lead commercial product. After being absorbed by Bristol Myers Squibb, Mirati no longer trades as an independent operating company, but its science and product platform remain strategically important inside a much larger global pharmaceutical organization.([news.bms.com](https://news.bms.com/news/corporate-financial/2024/Bristol-Myers-Squibb-Completes-Acquisition-of-Mirati-Therapeutics-Strengthening-and-Diversifying-Oncology-Portfolio/default.aspx?utm_source=openai)) Geographically, Mirati’s historical footprint was concentrated in the United States, with its San Diego base serving as the center of research and corporate operations. Today, any commercial and development activity tied to Mirati’s assets sits within Bristol Myers Squibb’s broader global infrastructure, while the market reference remains the U.S. exchange context, specifically NASDAQ for Mirati’s former listing and NYSE for Bristol Myers Squibb. Key recent developments include the acquisition close, the integration of KRAZATI into Bristol Myers Squibb’s oncology portfolio, and continued clinical and regulatory momentum around the drug in 2024.([news.bms.com](https://news.bms.com/news/corporate-financial/2024/Bristol-Myers-Squibb-Completes-Acquisition-of-Mirati-Therapeutics-Strengthening-and-Diversifying-Oncology-Portfolio/default.aspx?utm_source=openai))